Lead party: British International Investment (BII) (investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: KELIX Bio Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco, Egypt
Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity · Instrument: Equity · Equity stake: 1% · Fund: African Development Partners III (ADP III)
Investors/buyers: British International Investment (BII), Development Partners International (DPI), European Bank for Reconstruction and Development (EBRD)
Legal advisers: not identified in the source record.
Source: announced 1 November 2020. Original announcement: bii.co.uk.


